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ABSTRACT: A comprehensive cost model of wildlife rabies is presented. A total of 11 factors were viewed to comprise the 
diverse agricultural, insurance, medical, and veterinary expenses associated with rabies (i.e., pet vaccinations, livestock 
vaccinations, pet replacements, livestock replacements, pre-exposure prophylaxis for humans, post-exposure prophylaxis for 
humans, adverse medical reactions, animal conml activities, public health charges, quarantine costs, and human death settlements). 
These factor costs form the basis of potential savings to be gained fiom rabies control activities. Irrespective of incidence, per unit 
costs and ranges were found to be greatest for livestock replacement, post-exposure prophylaxis, adverse medical reactions, and 
human death settlements, with substantial costs of adverse medical reactions and human deaths ocnvring infrequently but due to 
potential insurance or litigation claims. Empirical studies are needed to document the incidence of these factors during pre- 
epizootic, epizootic, and post-epizootic phases of wildlife rabies. 
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INTRODUCTION 
The median number of annual human deaths fkom 
rabies in the U. S. is low- less than 3 per year (Childs 
2002, Krebs et al. 2003). Still, this disease poses a major 
economic and public health concern due to diverse costs 
incurred h m  human or domestic animal contacts with 
suspected rabid animals (Meltzer and Rupprecht 
1998a,b). 
Recent data (Childs 2002) show that rabies cases 
involving dogs (Canis familiaris) and cats (Felis catus) 
account for only 5 - 10% (QOOIyear) of all animal rabies 
cases. Conversely, the incidence of rabies in wildlife has 
increased dramatically in the past 25 years, with 7,967 
positive cases reported in 2002 (Krebs et al. 2003). 
Multiple variants of the rabies vllus occur in this country: 
bat (e.g., Eptesim  CUP, Lasionyctem noctivagans), 
coyote (Canis latrans), fox (e.g., Vulpes vulpes, Alopex 
lagopus), raccoon (Procyon lotor), and skunk (e.g., 
Mephitis mephitis, Spilogale putoris) (Childs 2002). 
Mammals infected with these variants occupy prescribed 
geographical regions, with bat-variant rabies overlapping 
many regions (Childs 2002). Interestingly, during the 
1990s bats accounted for three-fourths of the 32 human 
cases of rabies (Niezgoda et al. 2002). 
Uncertainty characterizes the economic costs of rabies 
throughout the U.S. While several studies have attempted 
to quantify individual medical (see Kreindel et al. 1998, 
Shwiff et al. In Manuscript, Uaaa et al. 1992) and 
veterinary (Meltzer 1996) costs, estimates of other 
potential costs associated with the disease remain 
unknown. Here, we describe a comprehensive model of 
the costs attributed to rabies. Minimum-maximum 
estimates of the individual event costs (i.e., per unit cost) 
related to 11 factors were derived using Internet sites, 
published reports, statistical data s e ~ c e s ,  and personal 
inquiries. This information helps to reduce the 
uncertainty of economic costs linked with rabies and to 
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identify key sources of potential savings that could result 
h m  wildlife rabies control activities, especially oral 
rabies vaccination (ORV) programs. 
COSTS-SAVINGS MODEL OF RABIES 
Theoretical Description 
In recent reviews, Meltzer and Rupprecht (1998% b) 
stated that rabies impacts the global economy as mainly 
human and domestic animal health costs- prevention and 
treatment. We extend this view and identify diverse 
agricultural, insurance, medical, and veterinary costs that 
can be attributed to outbreaks of the disease. The 
potential saving of all or a portion of these wsts is the 
benefit of rabies control. 
Meltzer (1996) published a cost-savings model of 
raccoon-variant rabies that viewed expenditures and 
savings ffom ORV to vary with stages of an epizootic 
(i.e., pre-, during-, and post-epizootic). He discussed pet 
vaccinations and post-exposure medical treatments as the 
two main factors determining the economic impacts of 
raccoon-variant rabies epizootics. During an epizootic, 
disease costs are driven by increased rates of animal 
vaccination and human treatment. As pet owners become 
focused on the protection of their animals from rabies, pet 
vaccinations increase; a d  as individuals learn of a rabies 
epizootic, they want more liberal dispensing of medical 
treatments for practically any suspicious animal bite or 
secondary contact with another exposed victim. 
Meltzer (1996) attributed potential savings from a 
raccoon-variant ORV Program to the difference between 
pre-epidemic (baseline) versus epidemic and post- 
epidemic costs for these vaccinations and medical 
treatments. We agree with Meltzer's (1996) model, but 
we contend that numerous cost variables behave similar 
to these two costs. Because few empirical data are 
available for these variables, the significance of these 
costs in wildlife rabies epizootics is largely unknown. 
Cost Equation 
The following equation describes our view of the 
wsts and potential savings associated with wildlife 
rahies: 
where CR is the additive cost ($US) of a multi-year 
epizootic of some wildlife-variant of rabies. This cost is 
attributed to 11 main independent variables: PV - pet 
vaccinations (n x $US/vaccination), LV - livestock 
vaccinations (n x $US/vaccination), PR - pet animal 
replacements (n x $US/animal for rabies-caused deaths), 
LR - livestock replacements (n x $USihead by species), 
PreEP - human pre-exposure-prophylaxis (n x $US/ 
- . .  
vaccination), PEP 1 hu& post-exposure-pr~phylawis (n 
x $US/treatments), AR - Adverse reaction charges (n x 
$US/event), PH - public health charges (n x $US/event 
for case investigations and laboratory tests), AC - animal 
control costs (n x $US/event ), Q - quarantine of sus- 
pected rabid animals (n x $US/event), HD - insured 
human death claims (n x $US/death). 
RELATIVE PER-UNIT COST ESTLMATES 
We gleaned low and high cost data for each factor in 
our model from Intemet sites, published reports, statistical 
data services, or personal inquiries. Descriptive para- 
graphs were used to explain the nature of these empirical 
values and a graph was prepared to show the relative 
minjmum-maximum difference in these factor wsts (see 
Figures l a  and lb). We converted reported cost values to 
- present values based on the intervening annual reported E I % z i p  
Consumer Price Indices (International Monetary Fund 9 
2003). 
Pet Vaccination (PV) 
Prices for rabies vaccine and animal examination 
varied h m  a low of $5.00 and $0.00 at cost-of-vaccine- 
only or "free" clinics (Humphrey 1971, Uaaa et al. 1992) 
to a high of $15.00 and $43.00, respectively (i.e., personal 
phone call by RTS to a veterinarian in New York, with 
the examination fee for a booster shot usually waived). A 
well-derived mean estimate of PV is $19.36 in 2003 US$ 
(see Meltzer 1996). During epizootics, many municipali- 
ties underwrite some PV costs and hold clinics that 
typically charge $5.00 for the vaccine, with local 
veterinarians volunteering their time to administer the 
injections. The recommended regimen for rabies PV is 
annually or triennially based upon the chosen vaccine, the 
prior immunization history, and local regulations 
(National Association of State Public Health Veterinari- 
ans Committee 2004). Many pet owners opt for annual 
PV, especially if a rabies epizootic occurs in their area. 
Livestock Vaccination (LV) 
Rabies vaccines for cattle, equines, and sheep are 
available; no vaccines for swine or goats are cwently 
approved (Briggs et al. 2002, National Association of 
State Public Health Veterinarians Committee 2004). 
Preventative vaccinations must be given to livestock 
annually; therapeutic vaccinations after onset of symp- 
Figure 1.  (A) Bar graph of low and high factor wsts 
obtained for the 11 factors in the rabiescost model; 
(B) bar graph of low and high factor costs with AR and HD 
removed (9 factors). 
toms (e.g., unusual behavior, unexplained choking, partial 
paralysis) are rarely effective due mainly to the slow 
onset of pathogenic signs and the progression of the 
disease before treatment (Humphrey 1971, Childs 2002). 
Few states maintain records of preventative or therapeutic 
rabies LV, with Texas a noteworthy exception (Wilson 
and Clark 2001). 
Charges for rabies LV also varied widely. Low and 
high charges ranged from $10.00 for the vaccine (rancher 
administering shot) to $50.00 for the vaccine and 
examination by a veterinarian and a $1.00 per mile "call 
charge", respectively. Assuming a 20-mile trip for the 
veterinarian, this higher cost would be $70.00. While 
authorization to purchase and to administer the vaccine is 
limited to veterinarians in many states, enforcement is 
poor; ranchers in some states can buy the vaccine directly 
from a veterinary supply store and administer the shots. 
Pet Replacement (PR) 
The cost of replacing a pet depends upon pedigree and 
lineage of the animal. We arbitrarily set the minimum 
and maximum PR costs for a non-pedigreed and 
pedigreed dog at $25.00 (i.e., local pound animal) and 
$1,000.00 (i.e., exclusive breeder and pedigreed animal 
with lineage documents), respectively. Replacement of a 
cat, ferret, or rodent would be priced within these values. 
Livestock Replacement (LR) 
The costs of LR can be derived from current market 
data. Granted, rancherslfannm could contend that this 
underestimates the investment in each animal due to life- 
long veterinary charges or long-term genetic breeding 
investments in an animal. Still, these market price 
valuations afford useful minimum and maximum cost 
estimates for livestock. [Note - The reader may verify 
suggested prices by checking available internet sites using 
diverse search engines; here, we provide representative 
example sites.] Replacement of a representative steer1 
heifer at current market value would cost $825 (i.e., 1,000 
Ib. @ $82.50/cwt; h~://usda.mdib.comell.eddre~orts 
lnassr/pricdpap-bb/2004/amr 0304.txt), replacement of a 
representative calf would cost $1 11 ( e ,  100 lb. @ 
$1 1 1.00Icwt; usda.marinlib.comell.eddre~orts/msr 
&ice /pa~-bb/soo4/amr 0304.txt), and replacement of a 
representative dairy cow would average $1,130 
usda.mannlib.comell.eddre~orts/nassr/pricdpap-bb/2004 
/ a m  0304.txt). Replacement of a sheep and lamb would 
cost approximately $62 (i.e., 150 lb. @ $41.20/cwt; 
usda.mdib.comell.eddre~orts/~ssr/~ricdpap-bb/2004 
laear 0304.txt) and $65 (i.e., 60 ib. @ $107.00/cwt; 
usda.mannlib.comell.eddre~ortd~ssr/~ricdpap-bb/2004 
Iamr 0304.txt), respectively. Horse prices varied with 
lineage and breed; we estimated this replacement cost at 
between $1,000.00 (i.e., riding horse) and $30,000.00 
(i.e., dressage or event mount; htt~://www.hhho~~e,com 
/showihorses.ph~rderb~=~,rice). 
Pre-Exposure Prophylaxis (Pre-EP) 
Preventative rabies prophylaxis is typically provided 
to some animal control, veterinary, and animal research 
professionals (Briggs et al. 2002, CDC 1999, Uaaa et al. 
1992). The treatment regimen involves three 1.0-ml in- 
tramuscular (IM) doses of Human Diploid Cell Vaccine 
(HDCV), Purified Chick Embryo Cell Vaccine (PCEC), 
or Rabies Vaccine Adsorbed P A )  on days 0, 7, and 
either 21 or 28; serologic monitoring then determines the 
use of booster shots usually once every 0.5 to 2 years 
depending upon risk of exposure (CDC 1999, Munay and 
Arguin 2000). 
Kreindel et al. (1998) estimated the median HDCV 
dose cost at $328 (i.e., $221 in 1998 dollars) with a 
minimum-maximum of $119 - $716 (i.e., $80 - $483 in 
1998 dollars). Based on these data and the prescribed 3- 
dose series for PreEP, we estimated that the current low 
and high charges for PreEP would be $357 and $2,148, 
respectively (i.e., excluding possible physician charges). 
Murray and Arguin (2000) reported a mean Pre-EP 3- 
dose intramuscular (IM) cost as $563 or $188/dose (i.e., 
$468 and $156/dose in 2000), with an additional $83 (i.e., 
$71 in 2000) for serologic verification of immunization- 
a mean total cost of $646. Interestingly, Uaaa et al. 
(1992) estimated the mean cost of Pre-EP at $2,683 
($1,860 reported for 1988 pre-epizootic phase with 
physician costs included) per treatment series (i.e., no 
variance reported). 
Post-Exposure Prophylaxis (PEP) 
A typical human PEP regimen is somewhat similar to 
Pre-EP; however, the wound is intiltrated with 20 1.U.kg 
Human Rabies Immune Globulin (HRIG) at the time of 
initial treatment and the rabies vaccine regimen entails 5 
repeated IM injections of HDCV, PCEC, or RVA on days 
0. 3.7. 14. and 28 lCDC 1999). 
. , , 
A nurdber of s h i e s  have provided empirical costs for 
PEP; high variance has characterized these estimates 
(Kreindel, et al. 1998, Shwiff et al. In Manuscript, Uhaa 
et al. 1992). Kreindel et al. (1 998) reported a median PEP 
cost of $2,688 ($2,376) that varied fiom a low of $1,174 
to a high of $5,031 (i.e., $1,038 to $4,447 reported for 
1996). Shwiff et al. (In Manuscript) reported a mean 
$2,254 PEP, minimum and maximum costs of $257 and 
$5,673, respectively (i.e., this low value was reported by 
one clinic and may have represented a partial PEP). Uhaa 
et al. (1992) reported a mean PEP cost of $1,586 ($1,138 
in 1990; no variance reported). Thus, using these 
empirical data, the minimum and maximum direct cost 
for a human PEP treatment today is $257 and $5,673, 
respectively, but typical direct PEP costs would be 
between $1,586 and $2,688. 
Adverse Reactions (AR) 
Adverse medical effects are linked with both PreEp 
and PEP (CDC 1999). Prior studies have shown that 30 - 
74% of HDCV recipients note local pain, redness, 
swelling, and itching at injection sites, 5 - 40% of HDCV 
recipients develop systemic reactions (e.g., headache, 
nausea, abdominal pain, dizziness), and 3 cases 
developed neurologic effects resembling Guillain-Bad 
syndrome which alleviated in 512 weeb (CDC 1999). 
Infiltration of a wound with HRIG has also been linked 
with localized pain and fever (CDC 1999). 
Studies to estimate the actual costs of these AR effects 
are non-existent. Individuals experiencing localized and 
mild systemic effects would probably rely on inexpensive 
"over-the-counter" analgesics or possibly make one or 
two additional visits to a primaq care physician. We 
arbitrarily estimated these costs as between $5.00 (e.g., 
aspirin, skin ointment) and $150.00 (e.g., 2 physician 
visits with no health insurance), respectively. Obviously, 
the few patients that experience neurologic side effects 
might seek some kind of insurance or malpractice 
remuneration; this could be sizable, depending upon the 
severity of the syndrome. We arbitrarily estimated these 
claims at between $00 and $250,000. 
Additionally, Shwiff et al. (In Manuscript) estimated 
the indirect patient costs of a rabies exposure at $680 (no 
variance reported), with alternative medicines, lost wages, 
travel, and other (e.g., day care, therapy) costs of $57, 
$140, $12, and $471, respectively (no variances reported). 
Some AR costs were probably contained in these indirect 
estimates. 
Public Health (PEQ 
To our knowledge, only Shwiff et al. (In Manuscript) 
have attempted to estimate a per unit case cost for public 
health intavention to deal with rabies. They reported a 
mean $121 wst (no variance reported) for personnel and 
related investigatory activities. 
Animal Control (AC) 
Shwiff et al. (In Manuscript) also reported an AC 
estimate, but this did not separate AC and Q charges. The 
mean wmbined AC and Q cost was reported as $290 (no 
variance reported). 
Quarantine (Q) 
Current national recommendations for a dog, cat, or 
fexret that bites a human require a 10-day isolation and 
observation period (National Association of State Public 
Health Veterinarians Committee 2004). For animals 
potentially exposed to a suspected or confirmed rabid 
animal, recommendations involve a 45-day isolation and 
observation period assuming that the biting animal is 
currently vaccinated; this isolation and observation period 
is extended to 6 months if the animal is not currently 
vaccinated for rabies (National Association of State 
Public Health Veterinarians Committee 2004). 
Of course, the capture of pets is common following a 
suspected exposure, whereas the capture of wildlife is 
rare. Despite the cited recommendations and circum- 
stances, most municipal or county governments impose 
the 10-day period in all cases- a questionable policy 
considering the long incubation period of rabies virus- 
213 days (Niezgoda et al. 2002). Most of these municipal 
and county governments use their own pound or local 
Humane Society facilities for holding animals; fees are 
billed to the pet owner or, in the case of captured wildlife, 
i n c d  by the municipality. Representative charges 
consist of a $40.00 impound fee and an $18.00/day 
maintenance fee ($220.00 total) for dogs and cats (pen. 
wmrnun., Scott Temple, Larimer County, CO Humane 
Society, 2003). Pets that were vaccinated for rabies and 
bite a person are usually wnfined (quarantined) at the 
owner's property for observation (no c o s t t  the risk of 
losing track of the pet is low. Livestock involved in 
suspected rabid wildlife exposures are usually corralled 
and observed at the stockman's ranch or farm (no cost). 
Human Death (HD) 
Obviously, it is difficult to place a monetary valuation 
on a human life; nevertheless, these deaths must be 
counted as rabies-incurred impacts. To quantify low and 
high impacts from these deaths, we arbitrarily assumed 
that costs are attributed simply to payment from life 
insurance policies at a low of $00 (uninsured) and a high 
of $500,000 per HD. This is a conservative valuation; 
many actuarial estimates would include loss of lifetime 
hture income in HD settlements. 
CONCLUSIONS 
Wildlife rabies has increased dramatically in the past 
decade. Economic impacts &om epizootic outbreaks of 
specific variants of this disease are exerted upon diverse 
agricultural, insurance, medical, and veterinary interests. 
Due to greater incidences, PV and human PEP have been 
cited traditionally as the major cost impacts of the 
disease; however, of the 11 factors included in our model, 
the maximum and largest ranges of per unit costs were 
associated with LR, PEP, AR, and HD, with the potential 
occurrence of high AR and HD costs rare events. 
Empirical studies to determine pre-epizootic, epizootic, 
and post-epizootic incidences for the factors are sorely 
needed to allow improved economic projections of actual 
costs of the disease. Determination of these incidences 
and relative cost components will reduce the uncertainty 
of economic impacts linked with wildlife rabies and will 
allow improved policy decisions involving the 
development and distribution of ORV for wildlife. 
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